

G093  
Xylenes

**Results of Testing**

Chemical Name	CAS No.	Study Code/Type	Protocol/Guideline	Species	Exposure	Dose/Concentration	No. per Group	Results	Reference
Xylenes (mixed)	1330-20-7	HECTOXCARC Carcinogenicity	National Toxicology Program (NTP)	F344/N rats	gavage, 1x/d., 5 d/wk, 103 weeks	0, 250, 500 mg/kg	50 male 50 female	No evidence of carcinogenicity in male or female rats at either dose level. At no site was the incidence of nonneoplastic or neoplastic lesions in dosed rats of either sex considered to be related to administration of xylenes.	NTP TR-327, Dec. 1986, NTIS PB87189684/AS
Xylenes (mixed)	1330-20-7	HECTOXCARC Carcinogenicity	National Toxicology Program (NTP)	B6C3F <sub>1</sub> mice	gavage, 1x/d., 5 d/wk, 103 weeks	0, 500, 1000 mg/kg	50 male 50 female	No evidence of carcinogenicity in male or female mice at either dose level. At no site was the incidence of nonneoplastic or neoplastic lesions in dosed mice of either sex considered to be related to administration of xylenes.	NTP TR-327, Dec. 1986, NTIS PB87189684/AS
Xylenes (mixed)	1330-20-7	HERTOXTERA Developmental toxicity	Non-TSCA Protocol/ Guideline (docket OPTS-42025)	rats	inhalation, 6 hr/d during a 131-day pre-mating period and 20-day mating period, mated females continued during gestation days 1-20 and lactation days 5-20	0, 60, 250, 500 ppm	[1] 30 males, 60 females (0 ppm); [ 2, 3] 10 males, 20 females (60, 250 ppm); [4] 20 males , 40 females (500 ppm); [5] 10 males (500 ppm), 20 females (0 ppm); [6] 10 males (0 ppm), 20 females (500 ppm);	No mortality occurred in any of the treated groups. No adverse treatment-related effects were observed during the pre-mating period for F0 adults. In groups 3 and 6, mating indices were significantly lower than control. In group 4, F0 females, there was a statistically significant increase in mean kidney weight. Mean fetal weights (females only) for the high-dose group were lower than control. The incidence of fetuses in the high-dose group with at least one ossification variation was slightly higher than control. No other treatment-related effects were observed.	Docket# OPTS-42025; American Petroleum Institute study HESD: 31-31481
Xylene, p-	106-42-3	HEDIRR Permeability coefficient (Kp)	69 FR 22402		in vitro			<b>TEST DATA IN REVIEW PROCESS</b>	71 FR 1538 1/10/06 OPPT-2003-0006
Xylene, p-	106-42-3	HEDIRR Dermal absorption	69 FR 22402		in vitro	10 minutes		<b>TEST DATA IN REVIEW PROCESS</b>	71 FR 1538 1/10/06 OPPT-2003-0006
Xylene, p-	106-42-3	HEDIRR Dermal absorption	69 FR 22402		in vitro	60 minutes		<b>TEST DATA IN REVIEW PROCESS</b>	71 FR 1538 1/10/06 OPPT-2003-0006